Impax looks to make Vitorin generic; Sawhney takes over as managing director at Ranbaxy;

@FiercePharma: Big Pharma's Top 5 Emerging Market Deals. Report | Follow @FiercePharma

> Impax Laboratories has initiated a challenge of patents listed by MSP Singapore in connection with Vytorin (ezetimibe/simvastatin), 10 mg/80 mg. Impax release

> Leading drugmaker Ranbaxy Laboratories today said Arun Sawhney has taken over as the managing director (MD) of the company, replacing Atul Sobti, who resigned on August 12. Report

> A small Northeast Philadelphia generic drug maker is taking on the FDA in a battle over a pain medicine that is more than a century old. Story

> Cephalon has filed a lawsuit in U.S. District Court in Delaware against Apotex for infringement of U.S. Patent Nos. 7,132,570 and RE37,516 for the Cephalon product Nuvigil. SEC filing

> A generic drug maker plans to make a version of the Gilead Sciences chronic hepatitis B drug Hepsera. News

Biotech News

 @FierceBiotech: VCs shell out $39M for Complete Genomics. Article | Follow @FierceBiotech

> Can Eli Lilly get its R&D act together? News

> HHS: U.S. needs $200M biodefense fund. Report

> MannKind looks to raise $110M. Item

> Anchor raises $10M, aims for more in Series B. Story

> Abbott bows out of Flutiform pact. Article

And Finally... It will likely be the most popular measure taken by the German government in almost two years: changing a law to allow medical cannabis to be prescribed by doctors and distributed through pharmacies. The law was spearheaded by a small coalition party, the pro-business Free Democrats (FDP). News

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.